Lactose (India) Limited (LACTOSE) Fair Value & Analysis
Healthcare · IN · Market cap ₹1.3B
Fair value as of: Jul 5, 2026
From 14 valuation models · updated 3 days ago
Share price −9.5% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹78.19 – ₹131.95 · fair‑value band ₹72.24 – ₹128.88 · the ₹103.75 price screens above the ₹102.11 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Lactose (India) Limited (LACTOSE) currently trades at ₹103.75, while our model-based Fair Value estimate is ₹102.11 — implying the stock looks roughly 1.6% overvalued today. We read business quality at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Lactose (India) Limited generated revenue of ₹1.6B at a net margin of 3.7%. Revenue grew 64.8% year over year. It earns a return on equity of 9.8%. Net debt stands at ₹611M. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹72.24 (bear case) to ₹128.88 (bull case); at ₹103.75, the current price sits within that range. The share trades about 24% below its 52-week high and 36% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside — at -2%, LACTOSE screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Lactose (India) Limited engages in the manufacture and trading of pharmaceutical products in India. The company is involved in the production of drugs, medicines, chemicals, foods, etc. It offers lactose monohydrate; dry granulated, film, and lacquer coated tablets; and pharmaceutical products in solid dose forms. In addition, the company provides disaccharide lactulose, an active pharmaceutical ingredient that is used in the treatment of constipation, hepatitis encephalopathy, intestinal microflora, dental care, diabetes, and chronic liver disease, as well as for use as a prebiotic. It also exports its products. The company was incorporated in 1991 and is headquartered in Mumbai, India.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Lactose (India) Limited reported revenue of ₹1.6B in FY2025 versus ₹459M in FY2021, a compound +37.3%/yr. Reported net income was ₹60.6M in FY2025, compounding +25.4%/yr from FY2021.
Is LACTOSE fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,457 | ₹1,329 | -70% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,278 | ₹595.34 | -53% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Lactose (India) Limited (LACTOSE) undervalued?
What is the fair value of LACTOSE?
What is the quality score of LACTOSE?
What is the revenue of Lactose (India) Limited (LACTOSE)?
What is the net profit margin of LACTOSE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.